115 related articles for article (PubMed ID: 26845757)
21. Cytologic features of granular cell astrocytoma in crush preparations.
Arvanitis LD; Gattuso P; Iacusso C
Diagn Cytopathol; 2011 Jan; 39(1):77-9. PubMed ID: 21162098
[No Abstract] [Full Text] [Related]
22. Classification of astrocytomas and malignant astrocytomas by principal components analysis and a neural net.
McKeown MJ; Ramsay DA
J Neuropathol Exp Neurol; 1996 Dec; 55(12):1238-45. PubMed ID: 8957447
[TBL] [Abstract][Full Text] [Related]
23. Manganese superoxide dismutase (MnSOD) is a malignant astrocytoma specific biomarker and associated with adverse prognosis in p53 expressing glioblastoma.
Shwetha SD; Shastry AH; Arivazhagan A; Santosh V
Pathol Res Pract; 2016 Jan; 212(1):17-23. PubMed ID: 26616112
[TBL] [Abstract][Full Text] [Related]
24. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
25. YKL-40 is directly produced by tumor cells and is inversely linked to EGFR in glioblastomas.
Horbinski C; Wang G; Wiley CA
Int J Clin Exp Pathol; 2010 Jan; 3(3):226-37. PubMed ID: 20224722
[TBL] [Abstract][Full Text] [Related]
26. MET immunolabelling is a useful predictive tool for MET gene amplification in glioblastoma.
Burel-Vandenbos F; Ngo-Mai M; Dadone B; Di Mauro I; Gimet S; Saada-Bouzid E; Bourg V; Almairac F; Fontaine D; Virolle T; Pedeutour F
Neuropathol Appl Neurobiol; 2017 Apr; 43(3):252-266. PubMed ID: 26946354
[TBL] [Abstract][Full Text] [Related]
27. [Molecular pathology of brain tumors].
Sanz Esponera J
An R Acad Nac Med (Madr); 2005; 122(1):191-6. PubMed ID: 16173698
[TBL] [Abstract][Full Text] [Related]
28. Moving the needle: Optimizing classification for glioma.
Verhaak RG
Sci Transl Med; 2016 Aug; 8(350):350fs14. PubMed ID: 27488893
[TBL] [Abstract][Full Text] [Related]
29. Grading astrocytomas.
Adelman LS
Neurosurg Clin N Am; 1994 Jan; 5(1):35-41. PubMed ID: 8124092
[TBL] [Abstract][Full Text] [Related]
30. Heterozygosity status of 1p and 19q and its correlation with p53 protein expression and EGFR amplification in patients with astrocytic tumors: novel series from India.
Jha P; Agarwal S; Pathak P; Srivastava A; Suri V; Sharma MC; Chosdol K; Srivastava T; Gupta D; Gupta A; Suri A; Sarkar C
Cancer Genet Cytogenet; 2010 Apr; 198(2):126-34. PubMed ID: 20362227
[TBL] [Abstract][Full Text] [Related]
31. Dual lineage of astrocytomas.
Bishop M; de la Monte SM
Am J Pathol; 1989 Sep; 135(3):517-27. PubMed ID: 2551172
[TBL] [Abstract][Full Text] [Related]
32. Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma.
Sahm F; Reuss D; Koelsche C; Capper D; Schittenhelm J; Heim S; Jones DT; Pfister SM; Herold-Mende C; Wick W; Mueller W; Hartmann C; Paulus W; von Deimling A
Acta Neuropathol; 2014 Oct; 128(4):551-9. PubMed ID: 25143301
[TBL] [Abstract][Full Text] [Related]
33. Experimental anti-angiogenesis causes upregulation of genes associated with poor survival in glioblastoma.
Saidi A; Javerzat S; Bellahcène A; De Vos J; Bello L; Castronovo V; Deprez M; Loiseau H; Bikfalvi A; Hagedorn M
Int J Cancer; 2008 May; 122(10):2187-98. PubMed ID: 18092325
[TBL] [Abstract][Full Text] [Related]
34. Computer-assisted discrimination of glioblastomas.
Scarpelli M; Montironi R; Thompson D; Bartels PH
Anal Quant Cytol Histol; 1997 Oct; 19(5):369-75. PubMed ID: 9349896
[TBL] [Abstract][Full Text] [Related]
35. Caveolin-1 expression in diffuse gliomas: correlation with the proliferation index, epidermal growth factor receptor, p53, and 1p/19q status.
Barresi V; Buttarelli FR; Vitarelli EE; Arcella A; Antonelli M; Giangaspero F
Hum Pathol; 2009 Dec; 40(12):1738-46. PubMed ID: 19716156
[TBL] [Abstract][Full Text] [Related]
36. Molecular heterogeneity of glioblastomas: does location matter?
Denicolaï E; Tabouret E; Colin C; Metellus P; Nanni I; Boucard C; Tchoghandjian A; Meyronet D; Baeza-Kallee N; Chinot O; Figarella-Branger D
Oncotarget; 2016 Jan; 7(1):902-13. PubMed ID: 26637806
[TBL] [Abstract][Full Text] [Related]
37. Mitosin and pHH3 predict poorer survival in astrocytomas WHO grades II and III.
Varughese RK; Lind-Landström T; Habberstad AH; Salvesen Ø; Haug CS; Sundstrøm S; Torp SH
J Clin Pathol; 2016 Jan; 69(1):26-34. PubMed ID: 26188054
[TBL] [Abstract][Full Text] [Related]
38. [Correlation between loss of heterozygosity on chromosome 1p and 19q and expression of MGMT, p53 and Ki-67 proteins in gliomas].
Huang L; Jiang T; Yuan F; Li GL; Xu LX; Cui Y
Zhonghua Zhong Liu Za Zhi; 2011 Oct; 33(10):752-8. PubMed ID: 22335907
[TBL] [Abstract][Full Text] [Related]
39. Established and emerging variants of glioblastoma multiforme: review of morphological and molecular features.
Karsy M; Gelbman M; Shah P; Balumbu O; Moy F; Arslan E
Folia Neuropathol; 2012; 50(4):301-21. PubMed ID: 23319187
[TBL] [Abstract][Full Text] [Related]
40. Mesenchymal/proangiogenic factor YKL-40 related to glioblastomas and its relationship with the subventricular zone.
Batista KMP; Eulate-Beramendi SA; Pińa KYÁR; Figueira PR; Canal AF; Chasin JMA; Meilan Á; Ugalde R; Vega IF
Folia Neuropathol; 2017; 55(1):14-22. PubMed ID: 28430288
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
